Industry News

• Abbott enhances pharmaceutical pipeline with acquisition of Facet Biotech  Abbott and Facet Biotech announced a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
  Abbott March 09, 2010  
• Vaccinating children against flu helps protect wider community  Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well.
  National Institutes of Health March 09, 2010  
• Cardiome reports 2009 results  Net income for the fourth quarter of 2009 (Q4-2009) was $12.6 million ($0.20 per common share), compared to a net loss of $8.3 million ($0.13 per common share) for the fourth quarter of 2008 (Q4-2008).
  Cardiome Pharma Corp. March 09, 2010  
• New data presented at American Burn Association's Annual Meeting  ZymoGenetics announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA.
  ZymoGenetics, Inc. March 09, 2010  
• Bristol-Myers Squibb and AstraZeneca announce the commencement of the SAVOR-TIMI 53  BMS and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA(TM)(saxagliptin).
  Bristol-Myers Squibb Company March 09, 2010  
• Monsanto to break ground on new breeding station in Mississippi  To better serve the needs of southern farmers, Monsanto plans to open a new corn breeding station in Flora, Mississippi. The $2.4 million facility further boosts the company's investment in the South and is a reflection of Monsanto's commitment to continue delivering new high-performing products.
  Monsanto Company March 09, 2010  
• Oncothyreon announces termination of arrangement agreement  Oncothyreon announced that Gamehost Income Fund has determined that certain proposed changes to the Income Tax Act (Canada) announced on March 4, 2010 by the Canadian Federal Minister of Finance will adversely affect the benefit to Gamehost of the arrangement between it and Oncothyreon.
  Oncothyreon Inc. March 09, 2010  
• Omeros licenses PDE7 compounds for Parkinson's disease program  Omeros announced that it has obtained an exclusive license to compounds from Asubio Pharma Co. for use in its PDE7 program, which is focused on the treatment of movement disorders.
  Omeros Corporation March 09, 2010  
• Sanofi-aventis and Merck to create a global leader in Animal Health  Sanofi-aventis and Merck & Co. announced that sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck's Animal Health business, to create a global leader in Animal Health.
  Merck & Co., Inc. March 09, 2010  
• OncoGenex reports financial results for fourth quarter and fiscal year 2009  Revenue for the fourth quarter and full year of 2009 was $25.5 million, consisting of partial recognition of the non-refundable up-front payments received from Teva in December 2009.
  OncoGenex Pharmaceuticals, Inc. March 08, 2010  

   (next 10 articles)